Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Measurement of Varicella-zoster virus antibody (procedure) |
Component |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella zoster virus antibody IgG measurement |
Component |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella-zoster virus antibody IgM measurement |
Component |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella-zoster immunoglobulin adverse reaction |
Causative agent (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Allergy to Varicella-zoster virus antibody |
Causative agent (attribute) |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely Varicella-zoster virus antibody 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely Varicella-zoster virus antibody 250 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Varicella-zoster virus antibody-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Anti-varicella-zoster ig injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Varicella zoster immune globulin 125 iu powder for injection solution vial (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Allergy to Varicella-zoster virus antibody |
Causative agent (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Immunoglobulin G antibody to Varicellovirus humanalpha3 (substance) |
Is a |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Varicella-zoster antibody level (procedure) |
Component |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicellovirus humanalpha3 IgM |
Is a |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Varicella-zoster virus antibody only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella-zoster virus antibody 104 unit/mL solution for injection |
Has precise active ingredient |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella-zoster virus antibody 104 unit/mL solution for injection |
Has basis of strength substance (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely Varicella-zoster virus antibody 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has precise active ingredient |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely Varicella-zoster virus antibody 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has basis of strength substance (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely Varicella-zoster virus antibody 250 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has basis of strength substance (attribute) |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely Varicella-zoster virus antibody 250 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Has precise active ingredient |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella-zoster virus antibody only product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Varicella-zoster virus antibody-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Antibody to Varicellovirus humanalpha3 (substance) |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |